Mineralocorticoid Receptor Antagonism in AKI: A New Hope?

AKI is a leading cause of morbidity and mortality in hospitalized patients, particularly among the critically ill, and its incidence is increasing.[1][1],[2][2] This has piqued the interest of renal researchers, leading to a massive surge in our knowledge of its pathogenesis, systemic effects, and

[1]  D. Gómez-Garre,et al.  A role for endothelin in the maintenance of post‐ischaemic renal failure in the rat. , 1991, The Journal of physiology.

[2]  G. Gamba,et al.  Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. , 2007, American journal of physiology. Renal physiology.

[3]  Norbert Lameire,et al.  Epidemiology of acute kidney injury. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[4]  G. Gamba,et al.  Adrenalectomy prevents renal ischemia-reperfusion injury. , 2009, American journal of physiology. Renal physiology.

[5]  Alexander Hillisch,et al.  A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule* , 2010, The Journal of Biological Chemistry.

[6]  B. Molitoris,et al.  Pathophysiology of ischemic acute kidney injury , 2011, Nature Reviews Nephrology.

[7]  G. Gamba,et al.  Recovery from ischemic acute kidney injury by spironolactone administration. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  H. Rabb,et al.  The distant organ effects of acute kidney injury. , 2012, Kidney international.

[9]  I. Koulouridis,et al.  World incidence of AKI: a meta-analysis. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[10]  P. Ponikowski,et al.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.

[11]  R. Zager,et al.  Progressive endothelin-1 gene activation initiates chronic/end stage renal disease following experimental ischemic-reperfusion injury , 2013, Kidney international.

[12]  G. Gamba,et al.  Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. , 2013, Kidney international.

[13]  L. Ruilope,et al.  Comparison of agents that affect aldosterone action. , 2014, Seminars in nephrology.

[14]  P. Kimmel,et al.  Acute kidney injury and chronic kidney disease as interconnected syndromes. , 2014, The New England journal of medicine.

[15]  W. Druml,et al.  Systemic consequences of acute kidney injury , 2014, Current opinion in critical care.

[16]  F. Eitner,et al.  Nonsteroidal antagonists of the mineralocorticoid receptor , 2015, Current opinion in nephrology and hypertension.

[17]  Michael Heung,et al.  Promoting Kidney Function Recovery in Patients with AKI Requiring RRT. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[18]  F. Jaisser,et al.  Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. , 2016, Journal of the American Society of Nephrology : JASN.